Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02BXA
|
||||
| Former ID |
DNC013513
|
||||
| Drug Name |
2-(2-(pyrrolidin-1-yl)ethyl)pyridine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C11H16N2
|
||||
| Canonical SMILES |
C1CCN(C1)CCC2=CC=CC=N2
|
||||
| InChI |
1S/C11H16N2/c1-2-7-12-11(5-1)6-10-13-8-3-4-9-13/h1-2,5,7H,3-4,6,8-10H2
|
||||
| InChIKey |
OXEFHEYEQUISKC-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Histamine H3 receptor | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Reactome | Histamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Monoamine Transport | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. Epub 2007 Oct 24.In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.